| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.9 |